Literature DB >> 10619855

Anticancer drug targets: growth factors and growth factor signaling.

J B Gibbs1.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10619855      PMCID： PMC382594          DOI： 10.1172/JCI9084

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  30 in total

1.  Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.

Authors:  W Du; A Liu; G C Prendergast
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 2.  Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

Authors:  J T Holmlund; B P Monia; T J Kwoh; F A Dorr
Journal:  Curr Opin Mol Ther       Date:  1999-06

3.  Paradoxical activation of Raf by a novel Raf inhibitor.

Authors:  C A Hall-Jackson; P A Eyers; P Cohen; M Goedert; F T Boyle; N Hewitt; H Plant; P Hedge
Journal:  Chem Biol       Date:  1999-08

4.  Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.

Authors:  S G Eckhardt; J Rizzo; K R Sweeney; G Cropp; S D Baker; M A Kraynak; J G Kuhn; M A Villalona-Calero; L Hammond; G Weiss; A Thurman; L Smith; R Drengler; J R Eckardt; J Moczygemba; A L Hannah; D D Von Hoff; E K Rowinsky
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

5.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

6.  Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

Authors:  M S Ewer; H R Gibbs; J Swafford; R S Benjamin
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 7.  Basic science of HER-2/neu: a review.

Authors:  M C Hung; Y K Lau
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 8.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Authors:  S Shak
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

9.  Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

Authors:  J Sun; M A Blaskovich; D Knowles; Y Qian; J Ohkanda; R D Bailey; A D Hamilton; S M Sebti
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

Review 10.  Analogs of staurosporine: potential anticancer drugs?

Authors:  A Gescher
Journal:  Gen Pharmacol       Date:  1998-11
View more
  18 in total

1.  Targeted therapies for killing tumor cells.

Authors:  A F Gazdar; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

4.  Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.

Authors:  Hisamitsu Ide; David B Seligson; Sanaz Memarzadeh; Li Xin; Steve Horvath; Purnima Dubey; Maryann B Flick; Barry M Kacinski; Aarno Palotie; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

Review 5.  Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.

Authors:  F Ciardiello
Journal:  Drugs       Date:  2000       Impact factor: 9.546

6.  Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Authors:  Zhimin Tong; Subhankar Chakraborty; Bokyung Sung; Pooja Koolwal; Sukhwinder Kaur; Bharat B Aggarwal; Sendurai A Mani; Robert S Bresalier; Surinder K Batra; Sushovan Guha
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

7.  Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.

Authors:  Cheng-Yu Tsai; J Cameron Finley; Sameh S Ali; Hemal H Patel; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

8.  Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells.

Authors:  Masaharu Hazawa; Kenji Takahashi; Koji Wada; Takao Mori; Norio Kawahara; Ikuo Kashiwakura
Journal:  Invest New Drugs       Date:  2009-09-26       Impact factor: 3.850

9.  Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

Authors:  Radhakrishna G Pillai; Martin Forster; Meg Perumal; Fraser Mitchell; Julius Leyton; Franklin I Aibgirhio; Oksana Golovko; Ann L Jackman; Eric O Aboagye
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

10.  Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.

Authors:  Heather B Adkins; Caterina Bianco; Susan G Schiffer; Paul Rayhorn; Mohammad Zafari; Anne E Cheung; Olivia Orozco; Dian Olson; Antonella De Luca; Ling Ling Chen; Konrad Miatkowski; Chris Benjamin; Nicola Normanno; Kevin P Williams; Matthew Jarpe; Doreen LePage; David Salomon; Michele Sanicola
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.